Amgen to buy Celgene’s psoriasis drug Otezla for $13.4 bln in cash

26 Aug 2019

Amgen Inc said on Monday it would
buy Celgene Corp's psoriasis drug Otezla for $13.4
billion in cash, clearing the way for Bristol-Myers Squibb
to go ahead with its $74 billion deal for Celgene.

Read full article at Reuters